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Thomas Laws1, James D. Blanchard2, Sarah V. Harding2 and Helen S. Atkins1,3
1 CBR Division, Defence Science and Technology Laboratory, Porton Down, Salisbury, UK, 2 Aradigm Corporation, Hayward,
CA, USA, 3 Biosciences, University of Exeter, Exeter, UK
Inhalation of Yersinia pestis can lead to pneumonic plague, which without treatment
is inevitably fatal. Two novel formulations of liposome-encapsulated ciprofloxacin,
‘ciprofloxacin for inhalation’ (CFI, Lipoquin©R ) and ‘dual release ciprofloxacin for inhalation’
(DRCFI, Pulmaquin©R ) containing CFI and ciprofloxacin solution, are in development.
These were evaluated as potential therapies for infection with Y. pestis. In a murine
model of pneumonic plague, human-like doses of aerosolized CFI, aerosolized DRCFI or
intraperitoneal (i.p.) ciprofloxacin were administered at 24 h (representing prophylaxis) or
42 h (representing treatment) post-challenge. All three therapies provided a high level of
protection when administered 24 h post-challenge. A single dose of CFI, but not DRCFI,
significantly improved survival compared to a single dose of ciprofloxacin. Furthermore,
single doses of CFI and DRCFI reduced bacterial burden in lungs and spleens to below
the detectable limit at 60 h post-challenge. When therapy was delayed until 42 h post-
challenge, a single dose of CFI or DRCFI offered minimal protection. However, single
doses of CFI or DRCFI were able to significantly reduce the bacterial burden in the spleen
compared to empty liposomes. A three-day treatment regimen of ciprofloxacin, CFI, or
DRCFI resulted in high levels of protection (90–100% survival). This study suggests that
CFI and DRCFI may be useful therapies for Y. pestis infection, both as prophylaxis and
for the treatment of plague.
Keywords: Plague, Yersinia pestis, liposomal drug delivery, ciprofloxacin, biological warfare agents, inhalation
exposure
INTRODUCTION
The Gram-negative bacterium Yersinia pestis is the causative agent of plague, a disease responsible
for the death of an estimated 200 million people through devastating pandemics such as the Black
Death (Perry and Fetherston, 1997). Due to improvements in living conditions and public health,
outbreaks are now relatively uncommon. However, in the last 5 years there have been cases of
plague reported in Uganda, Democratic Republic of Congo and Peru as well as sporadic disease
occurring in the USA, China, and Mongolia (Organisation, 2016). Furthermore, plague is endemic
in Madagascar where 308 people were infected and 81 died from the disease in the 2014–2015
season (Bertherat, 2015).
There are numerous cases throughout history of Y. pestis being used as a biological weapon
(BW). In the Middle Ages, the bodies of dead plague victims were thrown over the walls of a
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besieged Caffa city by the Tartars (Wheelis, 2002). More recently,
during the Second World War the Japanese offensive BW
program is alleged to have dropped fleas infected with Y. pestis
over parts of China (Harris, 1993). Even today there are concerns
that plague could be used as a BW as Y. pestis could be
accessed relatively easily (it can be found on every continent
except Australia), there is the potential for person to person
spread and the mortality rate of plague is high (Inglesby et al.,
2000).
In natural outbreaks, Y. pestis infections have primarily been
spread through bites from infected fleas, resulting in bubonic
plague in humans (Perry and Fetherston, 1997). These patients
suffer from swollen painful lymph nodes, known as buboes, as
well as fever and physical exhaustion. Patients with positive blood
cultures but no buboes are generally diagnosed with septicemic
plague (Perry and Fetherston, 1997). However, it is inhalation
of Y. pestis which results in the most severe form of the disease,
pneumonic plague; if untreated this has a mortality rate of 100%
(Crook and Tempest, 1992). Pneumonic plague usually begins
with nondescript flu-like symptoms, which then quickly develop
into severe pneumonia with coughing and bloody sputum. In the
2014–2015 outbreak in Madagascar, 7% of cases were pneumonic
plague (Bertherat, 2015). Furthermore, pneumonic plague can
develop secondarily following bubonic or septicemic plague
and this also has a high fatality rate (Perry and Fetherston,
1997).
Currently, there is no licensed vaccine available for use
in humans, although a plague vaccine has been developed
and is in human phase II clinical trials (Hart et al., 2012).
Current recommendations suggest treating plague with
streptomycin or gentamicin (both of which require intravenous
administration); potential alternatives are ciprofloxacin,
doxycycline or chloramphenicol (Inglesby et al., 2000). In
the event of a mass casualty situation, prophylaxis with oral
doxycycline or ciprofloxacin is recommended (Inglesby et al.,
2000) due to the ease of administration. However, to treat
pneumonic plague, therapy must be initiated early as very high
mortality rates have been observed in patients when therapy was
not initiated within 24 h of symptoms developing (Inglesby et al.,
2000).
Systemic antibiotics, in general, poorly treat lower respiratory
infections, such as those associated with cystic fibrosis, and
consequently inhaled antimicrobial agents which can directly
target the lung have been developed (Zhou et al., 2015;
Cipolla et al., 2016). A novel formulation of ciprofloxacin,
utilizing liposome-encapsulation technology, has been developed
by Aradigm Corporation specifically for inhalational delivery.
Liposomal ‘ciprofloxacin for inhalation’ (CFI) can provide high,
sustained concentrations of ciprofloxacin in the lung with
once daily dosing (Bruinenberg et al., 2010). Furthermore,
liposomes can be taken up by phagocytic cells enabling antibiotic
delivery to the intracellular site of infection (Chono et al.,
2008). A second formulation ‘dual release ciprofloxacin for
inhalation’ (DRCFI), containing a mixture of free and liposome-
encapsulated ciprofloxacin, has also been developed (Serisier
et al., 2013). The free ciprofloxacin part of this formulation can
immediately act upon the bacteria and may also act upon the
host as ciprofloxacin has immunomodulatory activity (Dalhoff,
2005).
Both formulations have been evaluated in human clinical
trials and DRCFI is currently in phase 3 clinical trials
for Pseudomonas aeruginosa infection in patients with non-
cystic fibrosis bronchiectasis (Bruinenberg et al., 2009, 2010;
Serisier et al., 2013 and https://clinicaltrials.gov/ct2/show/
NCT02104245). In addition to usefulness for public health
indications these inhaled formulations may offer an advantage,
compared to an oral or intravenous formulation, in the event of
a deliberate release of an aerosolized BW agent. If administered
early enough, inhalation of CFI/DRCFI could be used to target
the initial site of infection (the lung following inhalation of
aerosolized BW agents) and prevent establishment of infection.
As there is considerable clinical data available, this product
could be repurposed as a medical countermeasure for plague
under the FDA animal rule following pivotal efficacy studies
in animals. Therefore, to determine whether this formulation
offers an advantage over therapies currently licensed for plague
we have herein sought to compare its efficacy to ciprofloxacin
administration in humans (approved routes including oral or
intravenous).
In our previous studies, a single dose of aerosolized
CFI administered at 24 h post-challenge has provided full
protection against a lethal challenge of inhalational Francisella
tularensis Schu S4 infection in a murine model (Hamblin
et al., 2014a). In a non-lethal mouse model of Coxiella
burnetii infection, intranasally instilled CFI administered at
24 h post-challenge prevented weight loss and the development
of clinical signs associated with infection (Norville et al.,
2014). However, the efficacy of neither CFI nor DRCFI has
been evaluated in BW mouse models once the infection has
disseminated.
Yersinia pestis infection in the Balb/c mouse model is
well characterized with two distinct stages of infection (Heine
et al., 2013, 2014). At first the infection is localized to
the lung, and then it disseminates throughout the mouse
resulting in high bacterial burdens in multiple organs. Therapy
initiated during the first stage of infection models the
administration of prophylaxis to patients before symptoms
have appeared. Delaying the initiation of therapy until bacteria
are disseminated enables an approximation of the efficacy of
antibiotics in the treatment of symptomatic patients. Addressing
the potential need for post-exposure prophylaxis and to
treat symptomatic patients, in this study the Balb/c mouse
has been used to evaluate the likely efficacy of CFI and
DRCFI for both prophylaxis and treatment of pneumonic
plague.
MATERIALS AND METHODS
Bacteria
Yersinia pestis strain CO92 was cultured on blood agar
base original (BAB) supplemented with 0.02% haemin or in
BAB broth (15 g/L proteose peptone, 2.5 g/L liver digest,
5.0 g/L yeast extract, 5.0 g/L sodium chloride, all from Oxoid,
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UK). This strain has a minimum inhibitory concentration
of <0.063 mg/L for ciprofloxacin (Russell et al., 1998).
Bacteria were prepared for the animal challenge inoculum
by incubating several colonies (grown for 48 h at 28◦C
on agar plates) in broth for 40 h at 28◦C, with shaking
at 180 rpm. Actual inoculum concentration was determined
by enumeration of cultured bacteria on agar plates. All
experiments with Y. pestis were carried out in a Class III
microbiological safety cabinet complying with British Standard
5726.
Animals
All experiments with mice were carried out in accordance
with the UK Animal (Scientific Procedures) Act (1986). Female
BALB/cAnNCrl (BALB/c) mice, 8–10 weeks old and 20 g (±4 g),
were obtained from Charles River Laboratories (UK) where
they were implanted with a sub-cutaneous Pico transponder
(Uno BV, Netherlands), enabling individual animals to be traced
throughout the study. Mice were caged in groups of 5 in
polypropylene cages with a stainless steel mesh cover, integral
water bottle holder and diet hopper in an ACDP (UK) level 3
rigid wall isolator, complying with British Standard 5726. Corn
cob grade 10/14 (International Product Supplies [IPS], irradiated)
was used as a nesting material and a range of environmental
enrichment was used throughout the study including cellulose
dome home and aspen wood wool (IPS). Husbandry conditions
consisted of a 12-h light-dark cycle (350 to 400 Lux during the
day, 10 Lux during the night), 19 to 23◦C and 45 to 65% relative
humidity. Irradiated Labdiet rodent diet 5002 (IPS) and water
were freely available during the study. Mice were allowed to
acclimatize to their home cage environment for five days before
challenge.
Antibiotics
Ciprofloxacin (Ciproxin R©, Bayer), liposomal ciprofloxacin for
inhalation (CFI) (Aradigm, USA) and dual release ciprofloxacin
for inhalation (DRCFI) (Aradigm, USA) were used in this
study. Ciproxin, 2 mg/ml solution for infusion, and CFI
(ARD-3100, Lipoquin R©), 50 mg/ml liposome-encapsulated
ciprofloxacin (expressed as hydrochloride) were used as supplied.
DRCFI (ARD-3150, Pulmaquin R©), 35 mg/ml ciprofloxacin
hydrochloride, was produced by mixing equal volumes of
CFI and ciprofloxacin hydrochloride solution for inhalation
(20 mg/ml) (Aradigm, USA) immediately prior to use.
Identification of Appropriate Dosing
Regimens
Mice were administered either ciprofloxacin, CFI, or DRCFI.
Aerosolized CFI and DRCFI were administered using the
inhalational therapy system (ITS) (Hamblin et al., 2014a), with
6 ml of the drug formulation placed in the nebulizer. Mice were
exposed to the CFI (n = 30) or DRCFI (n = 30) aerosols for
20 or 15 min, respectively. Not all of drug in the nebulizer
was aerosolized, for example following a 20 min exposure
approximately 4 ml of CFI was aerosolized with 2 ml remaining
in the nebulizer. The majority of the drug passed through the
mouse exposure chamber and was collected in the impinger
placed after the exposure chamber (the air is moving through
the exposure chamber at 6 L/min whereas mouse respiration is
20 ml/min).
A single dose of ciprofloxacin (30 mg/kg) was administered
to mice (n = 30) via the intraperitoneal (i.p.) route. The mice
(n = 3 /time point/group ) were culled at 1, 10, 20, or 30 min
and 1, 1.5, 2, 4, 8, 12 h following ciprofloxacin administration and
1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI
or CFI administration. Blood sampling points were chosen based
upon the short half-life of ciprofloxacin and longer half-life of
CFI (Hamblin et al., 2014b). Blood and lungs (whole organ) were
collected post mortem for analysis. The lung doses following CFI
or DRCFI administration were calculated using the concentration
of ciprofloxacin in the lung samples at 1 min post-administration.
The concentration-time profile of ciprofloxacin in blood and
lung homogenate was determined using liquid chromatography
mass spectrometry (LC-MS) as previously described (Hamblin
et al., 2014a; Norville et al., 2014). Non-compartmental
pharmacokinetic (PK) analysis of the mean concentration–
time profiles of ciprofloxacin in the mouse lung and plasma
was performed using WinNonlin v.6.1 (Certara, USA). One-
compartmental PK analysis of the 15 min DRCFI exposure was
also completed to enable simulation of the longer, 30 min, DRCFI
exposure.
For comparison purposes, human lung doses were estimated
from in vitro measurements of droplet size distribution and
emitted dose from the jet nebulizer used clinically (Cipolla et al.,
2010).
Antibiotic Efficacy in BALB/c Mice
Two separate animal experiments were conducted; the first
experiment determined the efficacy of antibiotics administered
at 24 h post-challenge (the post-exposure prophylaxis study) and
the second experiment determined the impact of delaying the
initiation of therapy until 42 h post-challenge (the treatment
study). In these studies, the Y. pestis aerosol was generated
using a Collison nebulizer containing 20 ml of Y. pestis
strain CO92 at a concentration of approximately 2 × 109
CFU/ml and conditioned using a modified Henderson apparatus
(Druett, 1969). Mice were exposed to the aerosol, in groups
of 20, for 10 min via a head-only exposure chamber, with
aerosol sampling of the aerosol chamber performed using
an all-glass impinger (AGI-30; Ace Glass, USA) containing
PBS. Each mouse received a retained dose of approximately
1 × 104 CFU in the treatment study or 3 × 104 CFU in
the prophylaxis study (determined though enumeration of the
bacterial concentration in the aerosol with a calculation (Harper
and Morton, 1953) using Guyton’s formula (Guyton, 1947)).
The aerosol exposure system has previously been validated for
Y. pestis (Thomas et al., 2009). Exposing animals to an aerosol
of 1.52 × 109 CFU of Y. pestis, resulted in a lung dose of
1.76 × 104 ± 0.085 × 104 CFU (experimentally determined)
compared to an estimated retained dose of 1.9 × 104 CFU
(Thomas et al., 2009).
To determine the bacterial burden of mice administered
therapy as prophylaxis or treatment, groups of 5 mice received
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a single dose of i.p. ciprofloxacin, i.p. PBS, aerosolized empty
liposomes, aerosolized CFI or aerosolized DRCFI (administered
as described above, but with a 30 min exposure for DRCFI) at
24 or 42 h post-challenge. A 30 mg/kg dose of i.p. ciprofloxacin
administered produces a drug exposure which is similar to the
drug exposure observed in humans following a 500 mg dose of
oral ciprofloxacin. The empty liposome control was administered
using the ITS (Hamblin et al., 2014a) with 6 ml placed in
the nebulizer and mice exposed to the aerosol for 20 min.
Mice received approximately 2.8 mg/kg (lung dose) of lipid
which matches the lipid lung dose of CFI and DRCFI (2.7 and
3.2 mg/kg). All mice were culled at the onset of clinical signs in
the control group of mice administered PBS (at approximately
60 h post-challenge). Spleens and lungs were harvested and
processed to determine bacterial load. The limit of detection of
bacteria in these organs was 50 CFU/g in the lung and 200 CFU/g
in the spleen.
To determine survival following the Y. pestis challenge,
groups of 10 mice were administered therapy from 24 or
42 h post-challenge. The groups received a single dose
of antibiotic or 3 days of therapy; the mice receiving
3 days of therapy were dosed with ciprofloxacin twice daily
whereas CFI, DRCFI and empty liposome control were
administered once daily to model the human dosing regimen
(Serisier, 2012; Serisier et al., 2013). Mice were observed
for 35 days post-challenge and clinical signs were recorded
twice daily using a scoring system describing the extent of
piloerection, hunching, eye problems and locomotion with
scores of 0, 1, or 2 specified for each category. Humane end-
points were used to identify moribund mice and minimize
suffering.
Statistical Analysis
Graphs were constructed with PRISM (v6.0, GraphPad),
statistical analysis was conducted with SPSS (v21.0, IBM) and
power calculations were conducted with SPSS SamplePower
(v3.0 IBM). In previous Y. pestis studies using similar doses
of bacteria, mice began to succumb approximately 2.5 days
post infection with a high hazard rate (probability that each
mouse will succumb on a particular day) of approximately 1
(Thomas et al., 2009). We estimated that groups of 10 mice
would be sufficient to provide a power of ∼80% with reduction
in hazard rate to 0.25 (i.e., 25% of the normal virulence). No
equivalent CFI/DRCFI treatment survival data was available for
power calculation. For assessing differences in bacterial load,
we estimated that the group size of 5 would be sufficient to
show differences of 1.5 log10s with a ∼80% power as previous
data had suggested that the standard deviation of Y. pestis
colonization data (transformed to the logarithm of 10) would be
around 0.5 (Thomas et al., 2009). The high frequency of animals
where no bacteria could be recovered negated the possibility
for using parametric analysis and Mood’s median tests with
multiple comparisons used to compare bacterial colonization
of groups. Where no bacteria could be isolated a number of
0 was assigned. Survival data were compared using Logrank
tests. Differences of p < 0.05 were considered statistically
significant.
RESULTS
Identification of Appropriate Dosing
Regimens of i.p. Ciprofloxacin and
Inhaled CFI or DRCFI from Human PK
The AUC/MIC (area under the curve/minimum inhibitory
concentration) measurement has been shown to be the
PK parameter most strongly associated with the efficacy of
ciprofloxacin in animal models (Craig, 1998), although this has
not been validated for local treatment of lung infections. In this
study, administration of a single 30 mg/kg dose of ciprofloxacin,
via the intraperitoneal route, to Balb/c mice resulted in a drug
exposure which is similar to the drug exposure observed in
humans following a 500 mg dose of oral ciprofloxacin (see AUC
in Table 1).
Inhalational drug scaling between humans and animals relies
upon attempting to deliver the same amount of drug to the lung
per kg of body weight. In Phase II human clinical trials with
DRCFI, 6 ml (210 mg) was nebulized, the corresponding dose
delivered to the lung is approximately 0.8 mg/kg, assuming a
50-kg patient (Aradigm Corporation, unpublished data) which
is similar to the dose of CFI delivered to mice (see Table 1).
In this study, exposure to DRCFI resulted in a lower inhaled
ciprofloxacin dose (see Table 1). Therefore, in order to obtain a
similar dose of CFI and DRCFI, the length of exposure to DRCFI
was increased. Table 1 shows the PK parameters of the shorter
DRCFI exposure and the PK of the longer exposure simulated by
the one-compartment models.
The PK parameters of CFI and DRCFI demonstrate the
different distributions of ciprofloxacin following administration
of these therapies compared to ciprofloxacin administered by
the intraperitoneal route. As previously demonstrated in humans
(Bruinenberg et al., 2009, 2010; Serisier et al., 2013), in the Balb/c
mouse administration of CFI or DRCFI via the inhalational
route results in low systemic concentrations of ciprofloxacin
compared to ciprofloxacin delivered by the intraperitoneal route
(see Figure 1) with a greater than 10-fold decrease in the
plasma total exposure (as demonstrated by the AUC). Conversely,
and as may be expected, inhalational administration of CFI or
DRCFI produces a higher Cmax and extended half-life in the
lung (see Figure 1) resulting in a 20-fold higher overall exposure
in the mouse lung compared to ciprofloxacin delivered by the
intraperitoneal route.
A Single Dose of CFI Administered at
24 h Post-Challenge Offers a Higher
Level of Protection Against Y. pestis than
Ciprofloxacin
First, an early initiation of therapy was investigated, with therapy
administered from 24 h post-challenge. Using the Balb/c mouse
model of aerosolizedY. pestis infection, bacteria could be detected
(∼2 × 103 CFU/ml) in the lung of all animals at this time,
but no bacteria could be detected in the spleen or blood. The
control mice (treated with PBS or empty liposomes) succumbed
to the infection by day 4 post-challenge whereas a single dose
Frontiers in Microbiology | www.frontiersin.org 4 February 2017 | Volume 8 | Article 91
fmicb-08-00091 February 3, 2017 Time: 17:41 # 5
Hamblin et al. Liposomal Ciprofloxacin Therapy for Y. pestis
TA
B
LE
1
|P
ha
rm
ac
o
ki
ne
ti
c
p
ar
am
et
er
s
o
f
ci
p
ro
fl
o
xa
ci
n
in
B
al
b
/c
m
o
us
e
p
la
sm
a
an
d
lu
ng
ho
m
o
g
en
at
e
fo
llo
w
in
g
a
si
ng
le
d
o
se
o
f
in
tr
ap
er
it
o
ne
al
ci
p
ro
fl
o
xa
ci
n,
ae
ro
so
liz
ed
C
FI
,o
r
ae
ro
so
liz
ed
D
R
C
FI
an
d
co
m
p
ar
is
o
n
to
cl
in
ic
al
d
o
se
s.
D
ru
g
S
p
ec
ie
s
To
ta
la
d
m
in
is
te
re
d
D
o
se
Lu
ng
d
o
se
∗
T
is
su
e
C
m
ax
(µ
g
/m
l
o
r
µ
g
/g
)
T
m
ax
(h
)
A
U
C
(µ
g
hr
/m
lo
r
µ
g
hr
/g
)
T
1/
2
(h
)
C
L
(m
l/
h/
kg
o
r
m
g
/h
/k
g
)
C
ip
ro
flo
xa
ci
n
M
ou
se
(B
al
b/
c)
30
m
g/
kg
(i.
p.
)
Lu
ng
76
.6
0.
02
35
.0
1.
4
85
5
P
la
sm
a
16
.9
0
11
.6
1.
1
2,
59
3
H
um
an
50
0
m
g
(p
.o
.)
(L
et
tie
ri
et
al
.,
19
92
)
S
er
um
2.
7
±
0.
8
–
10
.7
±
2.
6
5.
7
±
1.
2
–
C
FI
M
ou
se
(B
al
b/
c)
10
m
g/
kg
∗
1
m
g/
kg
(2
0
m
in
ex
po
su
re
)
Lu
ng
∗∗
11
6
0.
02
77
3
7.
4
1.
19
P
la
sm
a
0.
30
0.
02
0.
94
7.
0
1,
00
7
H
um
an
30
0
m
g
(in
iti
al
lo
ad
ed
do
se
in
ne
bu
liz
er
)(
8)
P
la
sm
a
0.
11
1.
5
1.
22
A
U
C
(0
-∞
)
11
.0
4
N
A
D
R
C
FI
M
ou
se
(B
al
b/
c)
4
m
g/
kg
∗
0.
4
m
g/
kg
(1
5
m
in
ex
po
su
re
)
Lu
ng
54
0.
5
35
6
4.
8
1.
08
P
la
sm
a
0.
32
0.
25
0.
80
11
.3
42
4
8
m
g/
kg
∗
0.
8
m
g/
kg
(3
0
m
in
ex
po
su
re
)
Lu
ng
10
0.
8#
0.
02
#
71
0#
4.
9#
1.
13
#
P
la
sm
a
0.
40
#
0.
06
#
1.
76
#
3.
0#
45
4#
H
um
an
11
1
m
g
(in
iti
al
lo
ad
ed
do
se
in
ne
bu
liz
er
)∗
∗∗
P
la
sm
a
0.
17
0.
33
0.
92
A
U
C
(0
-∞
)
9.
4
N
A
H
um
an
da
ta
is
sh
ow
n
fo
r
co
m
pa
ris
on
,w
ith
ov
er
al
le
xp
os
ur
e
in
th
e
pl
as
m
a
(A
U
C
)s
im
ila
r
in
th
e
hu
m
an
cl
in
ic
al
tr
ia
ls
an
d
th
is
st
ud
y,
in
di
ca
tin
g
th
at
th
e
m
ou
se
do
se
is
a
re
al
is
tic
su
rr
og
at
e
fo
r
th
e
hu
m
an
do
se
.
N
A
,n
ot
av
ai
la
bl
e
∗ L
un
g
do
se
(d
et
er
m
in
ed
du
rin
g
ph
ar
m
ac
ok
in
et
ic
s
st
ud
y
fro
m
1
m
in
tim
e
po
in
t).
Ex
tr
ap
ol
at
io
n
fro
m
R
aa
be
et
al
.
(1
98
8)
su
gg
es
ts
th
at
th
e
2.
2
µ
m
m
as
s
m
ed
ia
n
di
am
et
er
pa
rt
ic
le
s
pr
od
uc
ed
by
th
e
P
ar
iL
C
S
pr
in
t
S
ta
r
re
su
lts
in
10
%
of
th
e
to
ta
li
nh
al
ed
do
se
de
po
si
tio
ns
in
th
e
pu
lm
on
ar
y,
br
on
ch
ia
la
nd
tr
ac
he
a
of
m
ic
e,
e.
g.
,f
or
a
1
m
g/
kg
lu
ng
do
se
th
e
to
ta
ld
os
e
w
ill
be
10
m
g/
kg
.
#
P
re
di
ct
ed
fro
m
15
m
in
ex
po
su
re
da
ta
us
in
g
co
m
pa
rt
m
en
ta
la
na
ly
si
s
pe
rfo
rm
ed
by
pe
rfo
rm
ed
us
in
g
W
in
N
on
lin
∗∗
D
at
a
fro
m
H
am
bl
in
et
al
.(
20
14
a)
in
cl
ud
ed
fo
r
co
m
pa
ris
on
.
∗∗
∗ P
.,
B
ru
in
en
be
rg
,
D
.
S
er
is
ie
r,
J.
B
la
nc
ha
rd
,
D
.
C
ip
ol
la
,
an
d
I.
G
on
da
.
Ef
fe
ct
s
an
d
m
od
ul
at
io
n
of
re
le
as
e
ra
te
of
in
ha
le
d
ci
pr
ofl
ox
ac
in
w
ith
lip
os
om
al
fo
rm
ul
at
io
ns
in
he
al
th
y
su
bj
ec
ts
an
d
pa
tie
nt
s
w
ith
br
on
ch
ie
ct
as
is
.
P
re
se
nt
ed
at
Eu
ro
pe
an
R
es
pi
ra
to
ry
S
oc
ie
ty
A
nn
ua
lC
on
gr
es
s,
B
ar
ce
lo
na
,
S
pa
in
.
A
bs
tr
ac
t
55
74
,
20
10
.
D
os
e
us
ed
in
P
ha
se
2
an
d
3
cl
in
ic
al
tr
ia
ls
ha
s
be
en
in
cr
ea
se
d
to
21
0
m
g
lo
ad
ed
do
se
to
gi
ve
a
lu
ng
do
se
of
0.
8
m
g/
kg
(A
ra
di
gm
,u
np
ub
lis
he
d
da
ta
).
P
K
da
ta
fo
r
th
is
do
se
w
ill
be
av
ai
la
bl
e
w
he
n
th
e
P
ha
se
3
tr
ia
lr
es
ul
ts
ar
e
pu
bl
is
he
d.
Frontiers in Microbiology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 91
fmicb-08-00091 February 3, 2017 Time: 17:41 # 6
Hamblin et al. Liposomal Ciprofloxacin Therapy for Y. pestis
FIGURE 1 | Lung and plasma concentration-time profile of ciprofloxacin administered as intraperitoneal (IP) ciprofloxacin or aerosolized CFI or
DRCFI to BALB/c mice. Mice were dosed with 30 mg/kg of IP ciprofloxacin, 1 mg/kg lung dose of aerosolized CFI or 1 mg/kg lung dose of aerosolized DRCFI.
Note the prolonged elimination of ciprofloxacin in lung and plasma as well as the reduced plasma concentrations when CFI or DRCFI is administered by inhalation
directly to the lung.
of ciprofloxacin resulted in 60% of mice surviving the lethal
challenge. However, a single dose of CFI afforded significantly
better protection than ciprofloxacin with all mice surviving until
the end of the experiment at day 35 (P = 0.029). There was no
significant difference between DRCFI and ciprofloxacin or CFI,
with a single dose of DRCFI treatment resulted in 80% survival.
When therapy was administered for 3 days, all therapies provided
full protection (see Figure 2).
A Single Dose of CFI or DRCFI
Administered at 24 h Post-Challenge
Reduces Bacterial Burden in Lung and
Spleen to Below the Limit of Detection at
60 h Post-Challenge
To further differentiate between CFI, DRCFI, and ciprofloxacin,
the bacterial burden in lungs and spleens of infected mice
was determined at the onset of clinical signs in the control
animals (those treated with PBS or empty liposomes). The
bacterial load was high in both lungs and spleens in the control
groups whereas all three antibiotics had profound effects on
bacterial load (see Figure 3). No bacteria were isolated from
the spleen of any antibiotic treated animal and, when compared
to controls, this represents significant reductions in spleen
bacterial loads (P = 0.023). CFI and DRCFI treatment also
reduced the lung bacterial loads to lower than the limit of
detection, significantly different to the empty liposome control
(P = 0.023). Intraperitoneal ciprofloxacin did reduce the lung
bacterial load compared to controls treated with intraperitoneal
PBS (P = 0.023) (see Figure 3), however, bacteria could still be
detected in 2 out of 5 mouse lungs. There were no significant
differences in bacterial loads among the different therapies.
CFI and DRCFI Can Offer a High Level of
Protection against Y. pestis When
Therapy is Delayed
The efficacy of CFI and DRCFI against systemic Y. pestis infection
was investigated. Specifically, administration of therapy was
delayed until 42 h. At this time point, there was a high bacterial
burden in the lungs (∼1× 106 CFU/organ) and bacteria could be
detected in the blood and spleen of 3 out of 5 mice with an average
bacterial burden of∼3× 104 CFU/ml and∼3× 105 CFU/organ,
respectively. All control mice succumbed to infection by day 4
except for 1 mouse dosed with empty liposomes which survived
until day 11 post-challenge. A single dose of all three therapies
did increase time to death compared to the controls (P < 0.001)
but did not offer a high level of protection. A single dose of
ciprofloxacin resulted in 60% survival, and a single dose of CFI
or DRCFI resulted in 20 and 10% survival, respectively. Here,
ciprofloxacin offered significantly better protection than DRCFI
(P = 0.016) but not when compared to CFI (P = 0.060) (see
Figure 4). However, impressively, three days of antibiotic therapy
offered high levels of protection with 100, 90, and 90% survival
afforded by ciprofloxacin, CFI, and DRCFI, respectively (see
Figure 4).
CFI Reduces Bacterial Burden in Lung
and Spleen to Below the Detectable
Limit at 60 h Post-challenge When
Initiation of Therapy Is Delayed Until 42 h
Post-challenge
The bacterial burden at the onset of clinical signs in control
animals challenged with Y. pestis was examined when therapy
was delayed until 42 h post-challenge. High bacterial loads were
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FIGURE 2 | Therapeutic efficacy of intraperitoneally delivered
ciprofloxacin, aerosolized CFI or DRCFI prophylaxis in a mouse model
of inhalational Yersinia pestis infection. BALB/c mice (n = 10/group) were
challenged via the aerosol route with approximately 1 × 104 CFU Y. pestis
strain CO92 and treated 24 h post-challenge with 30 mg/kg of intraperitoneal
(IP) ciprofloxacin, 300 µl IP PBS, aerosolized empty liposomes (2.8 mg/kg
lipid), 1 mg/kg lung dose of aerosolized CFI or DRCFI (2.7 and 3.2 mg/kg lipid,
respectively). Graphs show the survival of mice following (A) 1 dose of therapy
and (B) 3 days of therapy. All treatments improved survival compared to PBS
or empty liposome treatment (P < 0.001). Asterisks indicate other significant
differences in survival, ∗ for p = 0.029, ns indicates no significant difference
(P > 0.05). Note: animals receiving PBS, ciprofloxacin, CFI, and DRCFI were
exposed at the same time to the same aerosol.
present in the lungs and spleens of the control animals. In
comparison, bacterial numbers were reduced to levels below
a measureable threshold in the lungs and spleen of all the
mice treated with CFI and 3 of the 5 mice treated with
DRCFI. A comparison of bacterial numbers in the spleen and
lung indicated that the bacterial load had been reduced by all
three therapies when compared to their relevant control groups
(P = 0.023). Furthermore, both CFI and DRCFI treatment
significantly reduced bacterial burden in the lung compared
to ciprofloxacin treated mice (P = 0.023). CFI treatment also
FIGURE 3 | The effect of ciprofloxacin, CFI or DRCFI prophylaxis on
bacterial burden in a mouse model of inhalational Y. pestis infection.
BALB/c mice (n = 5/group) were challenged via the aerosol route with
approximately 1 × 104 CFU Y. pestis CO92 and treated 24 h post-challenge
with a single dose of 30 mg/kg intraperitoneal (IP) ciprofloxacin, 300 µl IP
PBS, aerosolized empty liposomes (2.8 mg/kg lipid), 1 mg/kg lung dose of
aerosolized CFI or DRCFI (2.7 and 3.2 mg/kg lipid, respectively). Graphs show
bacterial burden in lung and spleen at onset of clinical signs in control groups
(approximately 2.5 days post-challenge). Lines connect spleen and lung loads
from the same animal. LOD indicates samples which were below the limit of
detection. Asterisks indicate significant differences in bacterial burden
compared to the relevant control (i.e., CFI compared to empty liposomes, IP
ciprofloxacin compared to IP PBS), ∗for P < 0.05.
significantly reduced the spleen bacterial burden compared to
ciprofloxacin treatment (P = 0.023) (see Figure 5). However,
there was no significant difference in spleen bacterial burden
following DRCFI or ciprofloxacin therapy. In addition, there was
no significant difference in the lung or spleen bacterial burden of
CFI and DRCFI treated mice.
DISCUSSION
In the event of a deliberate release or a natural outbreak
of pneumonic plague, large numbers of patients and contacts
may have to receive antibiotics. Due to the low numbers
of natural cases, animal models are needed to evaluate the
efficacy of antibiotics against pneumonic plague. The well-
characterized Balb/c mouse model of pneumonic plague enables
antibiotic evaluation for prophylaxis and, by delaying therapy,
for treatment. In reality, those requiring treatment are likely to
be in-patients in a hospital, with dedicated medical care and
the potential for multiple therapies administered by medical
staff. In contrast, those requiring prophylaxis are likely to
have different requirements such as a therapy which can be
taken without medical supervision and with very few side
effects. Those receiving prophylaxis may include doctors or
soldiers who need to remain active and able to perform their
duties.
Delivery of a potent antibiotic directly to the site of the
primary infection, the lung, provides the opportunity for much
higher antibiotic concentration in proximity of the infection and
much lower systemic exposure to avoid systemic side-effects.
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FIGURE 4 | Therapeutic efficacy of ciprofloxacin, CFI or DRCFI
treatment in a mouse model of inhalational Y. pestis infection. BALB/c
mice (n = 10/group) were challenged via the aerosol route with approximately
3 × 104 CFU Y. pestis CO92 and treated 42 h post-challenge with 30 mg/kg
of intraperitoneal (IP) ciprofloxacin, 300 µl IP PBS, aerosolized empty
liposomes (2.8 mg/kg lipid), 1 mg/kg lung dose of aerosolized CFI or DRCFI
(2.7 and 3.2 mg/kg lipid, respectively). Graphs show the survival of mice
following (A) 1 dose of therapy and (B) 3 days of therapy. All treatments
improved survival compared to PBS or empty liposome treatment
(P < 0.001). Asterisks indicate significant differences in survival, ∗ for
p = 0.016, ns indicates there were no significant differences (P < 0.05).
Indeed, inhaled CFI has been shown to be safe and well tolerated
in a number of patient populations (Bruinenberg et al., 2009,
2010; Serisier et al., 2013). In addition, due to the altered route of
administration inhaled CFI or DRCFI therapy should minimize
gastro enteric side effects compared to oral ciprofloxacin. The
encapsulation of ciprofloxacin in liposomes enables the antibiotic
to be effective when delivered by inhalation. Free ciprofloxacin
delivered by the inhalation route has a very short half-life
(approximately 1 h) and is not an effective antimicrobial (Conley
et al., 1997; Wong et al., 2003). In addition, the free ciprofloxacin
aerosol is very irritating to the lung and is not tolerated very
well (Aradigm, unpublished). For these reasons an inhaled free
FIGURE 5 | Efficacy of ciprofloxacin, CFI or DRCFI treatment upon
bacterial burden in a mouse model of inhalational Y. pestis infection.
BALB/c mice (n = 5/group) were challenged via the aerosol route with
approximately 3 × 104 CFU Y. pestis CO92 and treated 42 h post-challenge
with a single dose of 30 mg/kg intraperitoneal (IP) ciprofloxacin, 300 µl IP
PBS, aerosolized empty liposomes (2.8 mg/kg lipid), 1 mg/kg lung dose of
aerosolized CFI or DRCFI (2.7 and 3.2 mg/kg lipid, respectively). Graphs show
bacterial burden in lung and spleen at onset of clinical signs in control groups
(approximately 2.5 days post-challenge). Lines connect spleen and lung loads
from the same animal. LOD indicates samples which were below the limit of
detection. All therapies significantly reduced bacterial burden compared to
their relevant control (P < 0.05). Asterisks indicate significant differences in
bacterial burden between therapies, ∗for P < 0.05 and ns for not significant.
ciprofloxacin formulation has not been developed for clinical
use.
In this study, when CFI or DRCFI were administered as
prophylaxis, at 24 h post challenge, they appear to be as good
as, i.p., ciprofloxacin at decreasing the bacterial burden in the
lung and spleen and thus reducing the lethality of plague.
This may be explained by the PK data which demonstrates
that administration of CFI or DRCFI greatly increases the
overall exposure to ciprofloxacin in the lung compared to
ciprofloxacin administered by intraperitoneal injection. This
high concentration of ciprofloxacin could prevent the disease
from disseminating from the initial site of infection in the
lung.
Delaying CFI or DRCFI treatment to 42 h post-challenge,
a time point at which the infection has become systemic,
also provided high levels of protection. This was somewhat
unexpected as the systemic exposure to ciprofloxacin (measured
by AUC in plasma) is more than 10-fold lower than ciprofloxacin
delivered by the intraperitoneal route. Furthermore, CFI and
DRCFI were able to reduce bacterial load in the spleen. This
may be explained by the hypothesis that liposome-encapsulated
antibiotics, like CFI, are taken up by macrophages in a similar
manner to the phagocytosis of bacteria (Alving, 1988; Chono
et al., 2008) and can alter the behavior of macrophages by
increasing phagocytosis and nitric oxide production (Wong et al.,
2000). If this is the case, ciprofloxacin loaded macrophages may
translocate from the lung to other organs around the body
(including the spleen) enabling a reduction in bacterial burden
far from the lung. However, although CFI treatment appears to
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reduce bacterial burden to a greater extent than ciprofloxacin,
this was not reflected in the pattern of survival, where a single
dose of CFI resulted in only a low level of protection. As
the disease progresses Y. pestis moves from an intracellular to
extracellular pathogen, therefore although there are low bacterial
numbers in the site of treatment (lung) and the leukocyte rich
tissues (spleen) due to CFI treatment there may be other foci of
infection enabling the disease to re-emerge. However, increasing
the therapy regimen of CFI or DRCFI to three days enables the
systemic infection to be successfully treated and offers a high level
of protection.
In human clinical trials treating Pseudomonas aeruginosa
infections in patients with non-cystic fibrosis bronchiectasis,
DRCFI appeared more efficacious than CFI in terms of reduction
of bacterial burden in the sputum (Serisier, 2012; Serisier
et al., 2013). The free ciprofloxacin component has been
hypothesized to provide an immediately acting antibiotic, while
the liposome-encapsulated component allows the concentration
of ciprofloxacin to remain high, through the slow release
of ciprofloxacin from the liposomes. In the Y. pestis mouse
infection model used in this study, there appeared to be no
significant difference between the formulations. Perhaps this
is due to differences in the pathogenesis of P. aeruginosa
in bronchiectasis and a Y. pestis infection. Alternatively, this
may be a limitation of the mouse model, with differences
in the efficacy of CFI and DRCFI not reflective of the
situation in humans. Further work investigating efficacy in
alternative models of infection, such as NHPs, is required to
determine whether CFI or DRCFI may be more effective against
Y. pestis.
To summarize, in this study liposome-encapsulated
antibiotics delivered by the inhalational route offer significant
protection against Y. pestis when administered as post-exposure
prophylaxis or as treatment. These results combined with
previously published data showing the efficacy of CFI against
F. tularensis and C. burnetii suggest that CFI and DRCFI have
broad spectrum activity and the potential for use against multiple
inhaled bacterial pathogens that pose a BW threat. Further work
with CFI and DRCFI is therefore warranted, with the view to
make a readily available, self-administrable, effective and safe
broad-spectrum product for prophylaxis and treatment even
though the exact nature of the pathogen may not be known.
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